Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential canonical 1 (TRPC1)
- Target
- TRPC1
- Molecular classification
- Ion channel, Receptor-operated cation channel, Transient receptor potential (TRP) channel superfamily, TRPC (canonical) subfamily
01
Overview
Transient receptor potential canonical 1 (TRPC1) is a nonselective cation channel found on the plasma membrane, encoded by the TRPC1 gene in humans. It is a founding member of the TRPC (canonical) subfamily within the larger transient receptor potential (TRP) ion channel superfamily. TRPC1 mediates calcium and sodium influx in response to depletion of intracellular calcium stores or activation of cell-surface receptors linked to phospholipase C signaling. Widely expressed in many tissues, including the brain, heart, and kidney, it plays a role in cellular calcium homeostasis and has been implicated in neurophysiological processes, cardiac function, and several pathologies. TRPC1 forms tetrameric complexes and can physically associate with other TRPC family members (TRPC3, TRPC4, TRPC5), acting as a regulator of channel activity. To date, there are no TRPC1-specific drugs, and pharmacological research is focused on developing more selective molecular modulators for this channel.
- Other names
- Short transient receptor potential channel 1TRP-related protein 1TRP1TRP channel protein C1Cation channel protein TRPC1
02
Mechanism of action
Pharmacological modulation of channel gating to alter Ca2+ flux (activation or inhibition of TRPC1-containing channels), indirect targeting via pathways affecting channel assembly or trafficking
03
Biological functions
Store-operated calcium entrySignal transductionRegulation of intracellular calcium concentrationCellular response to receptor stimulation via phospholipase C pathway
04
Disease associations
Cardiovascular disease (hypertension, cardiac hypertrophy)Neurodegenerative disease (role in neuronal signaling)Cancer (cell proliferation, migration)Kidney disease
05
Safety considerations
Potential for off-target effects due to broad tissue distribution and lack of subtype-selective drugsModulation may affect excitable and non-excitable tissues leading to cardiac, neuronal, or renal adverse effects
06
Interacting drugs
No approved drugs are highly selective for TRPC1; tool compounds and small molecules for TRPC channel modulation exist but are generally nonselective among TRPC family members
07
Biomarkers
There are no clinical biomarkers specifically validated for TRPC1; research settings may use TRPC1 expression as a marker for disease progression (e.g. cancer, cardiac disease), but not established in clinical practice
Beyond the preview
Go deeper on Transient receptor potential canonical 1 (TRPC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transient receptor potential canonical 1 (TRPC1).